WO2011122770A3 - Magnetic resonance imaging contrast agent coated with polymer having mannose-modified terminal, and preparation method thereof - Google Patents

Magnetic resonance imaging contrast agent coated with polymer having mannose-modified terminal, and preparation method thereof Download PDF

Info

Publication number
WO2011122770A3
WO2011122770A3 PCT/KR2011/001544 KR2011001544W WO2011122770A3 WO 2011122770 A3 WO2011122770 A3 WO 2011122770A3 KR 2011001544 W KR2011001544 W KR 2011001544W WO 2011122770 A3 WO2011122770 A3 WO 2011122770A3
Authority
WO
WIPO (PCT)
Prior art keywords
polymer
magnetic resonance
resonance imaging
contrast agent
mannose
Prior art date
Application number
PCT/KR2011/001544
Other languages
French (fr)
Korean (ko)
Other versions
WO2011122770A9 (en
WO2011122770A2 (en
Inventor
윤성준
전수연
강상현
정용연
박인규
조종수
유미경
Original Assignee
주식회사 인트론바이오테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 인트론바이오테크놀로지 filed Critical 주식회사 인트론바이오테크놀로지
Publication of WO2011122770A2 publication Critical patent/WO2011122770A2/en
Publication of WO2011122770A3 publication Critical patent/WO2011122770A3/en
Publication of WO2011122770A9 publication Critical patent/WO2011122770A9/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1857—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. PLGA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
    • A61K49/1848—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a silane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
    • A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
    • A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
    • A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
    • A61K49/1851—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule
    • A61K49/1863—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with an organic macromolecular compound, i.e. oligomeric, polymeric, dendrimeric organic molecule the organic macromolecular compound being a polysaccharide or derivative thereof, e.g. chitosan, chitin, cellulose, pectin, starch

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

The present invention relates to a magnetic resonance imaging contrast agent surface-coated with a polymer which has high stability in the body and biocompatibility, and more specifically, to a superparamagnetic magnetic resonance imaging contrast agent coated with a polymer having a mannose-modified terminal which can be used for enhancing the contrast of images in lymphography, and a preparation method thereof. The superparamagnetic magnetic resonance imaging contrast agent coated with a polymer having a mannose-modified terminal according to the present invention can provide high stability in the body and biocompatibility and can be used for easy diagnosis of the metastasis of cancer to lymph nodes.
PCT/KR2011/001544 2010-03-29 2011-03-07 Magnetic resonance imaging contrast agent coated with polymer having mannose-modified terminal, and preparation method thereof WO2011122770A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2010-0027634 2010-03-29
KR20100027634A KR101143257B1 (en) 2010-03-29 2010-03-29 MRI contrast agent coated with mannose-conjugated polymer and method for producing the same

Publications (3)

Publication Number Publication Date
WO2011122770A2 WO2011122770A2 (en) 2011-10-06
WO2011122770A3 true WO2011122770A3 (en) 2012-01-26
WO2011122770A9 WO2011122770A9 (en) 2012-03-22

Family

ID=44712709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/001544 WO2011122770A2 (en) 2010-03-29 2011-03-07 Magnetic resonance imaging contrast agent coated with polymer having mannose-modified terminal, and preparation method thereof

Country Status (2)

Country Link
KR (1) KR101143257B1 (en)
WO (1) WO2011122770A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101905620B1 (en) * 2017-02-09 2018-11-21 아주대학교산학협력단 The fluorescence magnetic silica nanoparticle using the silane-lanthanide chelate complex and magnetic particle, and method of manufacturing the same
KR102166606B1 (en) * 2018-10-12 2020-10-16 한국교통대학교산학협력단 Macrophage target nanoassembly and composition for anti-inflammation comprising the same
CA3158357A1 (en) 2019-11-21 2021-05-27 Ferronova Pty Ltd Magnetic tracer compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072713A1 (en) * 2000-08-11 2003-04-17 Johannes Platzek Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses
KR20080009682A (en) * 2005-04-01 2008-01-29 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 Poly(peptide)as a chelator : methods of manufacture and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030072713A1 (en) * 2000-08-11 2003-04-17 Johannes Platzek Use of perfluoroalkyl-containing metal complexes as contrast media in MR-imaging for visualization of plaque, tumors and necroses
KR20080009682A (en) * 2005-04-01 2008-01-29 더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 Poly(peptide)as a chelator : methods of manufacture and uses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONROY SUN ET AL.: "Folic acid-PEG conjugated superparamagnetic nanoparticles for targeted cellular uptake and detection by MRI", JBMR, vol. 78, no. 3, 2006, pages 550 - 557, XP008125666, DOI: doi:10.1002/JBM.A.30781 *
YURIKO HIGUCHI ET AL.: "Mannosylated semiconductor quantum dots for the labeling of macrophages", JOURNAL OF CONTROLLED RELEASE, vol. 125, no. 2, 2008, pages 131 - 136, XP022402141 *

Also Published As

Publication number Publication date
WO2011122770A9 (en) 2012-03-22
WO2011122770A2 (en) 2011-10-06
KR20110108447A (en) 2011-10-06
KR101143257B1 (en) 2012-07-13

Similar Documents

Publication Publication Date Title
EP2673006A4 (en) Method of preparing iron oxide nanoparticles coated with hydrophilic material, and magnetic resonance imaging contrast agent using the same
WO2011150212A3 (en) Magnetic nanoparticles
EP2723392A4 (en) Mri contrast agent for lymphography based on iron oxide nanoparticles and method for imaging lymph node using the same
SG11201400944QA (en) Biocompatible nanoparticles with aggregation induced emission characteristics as fluorescent bioprobes and methods of using the same for in vitro and in vivo imaging
EP2990382A4 (en) Magnetic iron oxide nanoparticle powder, process for producing same, thin film of magnetic iron oxide nanoparticles comprising said magnetic iron oxide nanoparticle powder, and process for producing same
EP2658527A4 (en) Nanoparticle and surface-modified particulate coatings, coated balloons, and methods therefore
WO2012154332A3 (en) Stable nanoparticles for highly saline conditions
EP2265174A4 (en) Functionalized magnetic nanoparticles and methods of use thereof
WO2011050177A8 (en) Paa nanoparticles for enhancement of tumor imaging
EP2492927A4 (en) Ferromagnetic particle powder, method for producing same, anisotropic magnet and bonded magnet
HK1180633A1 (en) Iron oxide magnetic nanoparticle, its preparation method and its use in desulfurization
EP2620955A4 (en) Ferromagnetic particle powder, method for producing same, anisotropic magnet, and bonded magnet
WO2012110835A3 (en) Prussian blue based nanoparticle as multimodal imaging contrast material
EP2625504A4 (en) Magnetic particle based biosensor
EP2658896A4 (en) Biocompatible agent for dispersing nanoparticles into an aqueous medium using mussel adhesive protein-mimetic polymer
EP2609935A4 (en) Switching fluorescent nanoparticle probe and fluorescent particle imaging method using same
WO2010094043A3 (en) Gadolinium expressed lipid nanoparticles for magnetic resonance imaging
WO2010091183A3 (en) Non-invasive detection of complement-mediated inflammation using cr2-targeted nanoparticles
EP2636365A4 (en) Magnetic resonance imaging device and magnetic resonance imaging method
MX2012007041A (en) Manganese chelates and their use as contrast agents in magnetic resonance imaging (mri).
EP2623028A4 (en) Magnetic resonance imaging device and magnetic resonance imaging method
EP2739291A4 (en) Oxide ferrimagnetics with spinel structure nanoparticles and iron oxide nanoparticles, biocompatible aqueous colloidal systems comprising nanoparticles, ferriliposomes, and uses thereof
PL401706A1 (en) Superparamagnetic iron oxide nanoparticles with the ultra-thin polymer films, their production and use
EP2598443A4 (en) Process for obtaining functionalized nanoparticulate magnetic ferrites for easy dispersion and magnetic ferrites obtained through the same
EP2984482A4 (en) Biopharmaceutical aggregation assessment and counterfeit detection using magnetic resonance relaxometry

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11762942

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11762942

Country of ref document: EP

Kind code of ref document: A2